Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.
作者信息
Kitadate Akihiro, Kobayashi Hiroki, Abe Yoshiaki, Narita Kentaro, Miura Daisuke, Takeuchi Masami, Matsue Kosei
机构信息
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, Kamogawa, Japan.
出版信息
Haematologica. 2020 Jan;105(1):e37-e40. doi: 10.3324/haematol.2019.219683. Epub 2019 Apr 19.
Abstract
摘要
相似文献
1
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.治疗前CD38阳性调节性T细胞影响复发/难治性多发性骨髓瘤患者对达雷妥尤单抗的持久反应。
Haematologica. 2020 Jan;105(1):e37-e40. doi: 10.3324/haematol.2019.219683. Epub 2019 Apr 19.
2
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.高参数液质联用流式细胞术评估达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者的疗效，结果表明免疫调节是一种新的作用机制。
Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.
3
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
4
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.在三重难治性多发性骨髓瘤患者中再次使用抗CD38单药治疗是一种可行且安全的方法。
Br J Haematol. 2016 Aug;174(3):473-7. doi: 10.1111/bjh.13776. Epub 2015 Oct 12.
5
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.CD38 表达和补体抑制剂影响多发性骨髓瘤患者对达雷妥尤单抗治疗的反应和耐药性。
Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.
6
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.接受抗CD38单克隆抗体达雷妥尤单抗治疗多发性骨髓瘤患者的输血前免疫血液学检测的注意事项
Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707.
7
Immunomodulatory effects of CD38-targeting antibodies.靶向 CD38 的抗体的免疫调节作用。
Immunol Lett. 2018 Jul;199:16-22. doi: 10.1016/j.imlet.2018.04.005. Epub 2018 Apr 24.
8
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.达雷妥尤单抗：一种用于治疗多发性骨髓瘤的首创CD38单克隆抗体。
J Hematol Oncol. 2016 Jun 30;9(1):51. doi: 10.1186/s13045-016-0283-0.
9
Daratumumab: A review of current indications and future directions.达雷妥尤单抗：现有适应证的回顾与未来方向。
Semin Oncol. 2022 Feb;49(1):48-59. doi: 10.1053/j.seminoncol.2022.01.008. Epub 2022 Jan 20.
10
Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
引用本文的文献
1
Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma.功能多组学揭示了多发性骨髓瘤中表面CD38的遗传和药理调控。
Blood Neoplasia. 2024 Jun 10;1(3):100025. doi: 10.1016/j.bneo.2024.100025. eCollection 2024 Sep.
2
Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression.伴有1q获得/扩增的多发性骨髓瘤通过白细胞介素-6受体过表达导致CD38表达降低。
Br J Haematol. 2025 Jun;206(6):1615-1626. doi: 10.1111/bjh.20106. Epub 2025 Apr 22.
3
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.患者报告结局对达雷妥尤单抗治疗的多发性骨髓瘤生存及不良事件的预测和预后意义
Eur J Haematol. 2025 Jun;114(6):1020-1031. doi: 10.1111/ejh.14410. Epub 2025 Mar 14.
4
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.MajesTEC-1研究中复发/难治性多发性骨髓瘤患者免疫适应性与对替卡泊单抗反应的相关性
Blood. 2024 Aug 8;144(6):615-628. doi: 10.1182/blood.2023022823.
5
Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.达雷妥尤单抗治疗“真正虚弱”的老年骨髓瘤患者。
Life (Basel). 2024 Mar 15;14(3):389. doi: 10.3390/life14030389.
6
Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.使用患者来源的体外模型确定复发/难治性多发性骨髓瘤患者对达雷妥尤单抗治疗的临床反应
EJHaem. 2023 Nov 29;5(1):141-146. doi: 10.1002/jha2.824. eCollection 2024 Feb.
7
What happens to regulatory T cells in multiple myeloma.多发性骨髓瘤中调节性T细胞会发生什么变化。
Cell Death Discov. 2023 Dec 21;9(1):468. doi: 10.1038/s41420-023-01765-8.
8
Mass cytometry analysis reveals altered immune profiles in patients with coronary artery disease.质谱流式细胞术分析揭示了冠心病患者免疫图谱的改变。
Clin Transl Immunology. 2023 Nov 2;12(11):e1462. doi: 10.1002/cti2.1462. eCollection 2023.
9
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma.绝对淋巴细胞计数在达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者中的预测作用。
Korean J Intern Med. 2023 Mar;38(2):238-247. doi: 10.3904/kjim.2022.183. Epub 2023 Jan 26.
10
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.骨髓微环境中的多发性骨髓瘤治疗。
Curr Oncol. 2022 Nov 21;29(11):8975-9005. doi: 10.3390/curroncol29110705.
本文引用的文献
1
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.达雷妥尤单抗单药治疗对三重难治性骨髓瘤的深度持续反应与T细胞扩增相关。
Exp Hematol Oncol. 2018 Feb 7;7:3. doi: 10.1186/s40164-018-0096-7. eCollection 2018.
2
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.在接受达雷妥尤单抗治疗的患者中，单核细胞和粒细胞降低骨髓瘤细胞上 CD38 的表达水平。
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.
3
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.达雷妥尤单抗联合泊马度胺及地塞米松治疗复发和/或难治性多发性骨髓瘤
Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.
4
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.达雷妥尤单抗对CD38的长期饱和作用会干扰骨髓瘤细胞的诊断检测。
Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.
5
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.isatuximab联合来那度胺及地塞米松治疗复发/难治性多发性骨髓瘤的1b期研究
Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.
6
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.靶向 CD38 抑制调节性 T 细胞的诱导和功能，减轻多发性骨髓瘤中的免疫抑制。
Clin Cancer Res. 2017 Aug 1;23(15):4290-4300. doi: 10.1158/1078-0432.CCR-16-3192. Epub 2017 Mar 1.
7
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
8
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
9
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.CD38 表达和补体抑制剂影响多发性骨髓瘤患者对达雷妥尤单抗治疗的反应和耐药性。
Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.
10
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
Zotero 插件